Guggenheim Capital LLC trimmed its stake in CVS Health Corp (NYSE:CVS) by 20.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 247,507 shares of the pharmacy operator’s stock after selling 62,454 shares during the period. Guggenheim Capital LLC’s holdings in CVS Health were worth $14,684,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sofos Investments Inc. bought a new position in shares of CVS Health in the 4th quarter worth $74,000. FSA Wealth Management LLC bought a new position in shares of CVS Health in the 4th quarter worth $28,000. New England Investment & Retirement Group Inc. bought a new position in shares of CVS Health in the 1st quarter worth $25,000. Filbrandt Wealth Management LLC bought a new position in shares of CVS Health in the 4th quarter worth $33,000. Finally, Solstein Capital LLC bought a new position in shares of CVS Health in the 4th quarter worth $35,000. 76.09% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP James David Clark sold 3,030 shares of the company’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $60.00, for a total value of $181,800.00. Following the sale, the senior vice president now owns 12,790 shares in the company, valued at $767,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alan Lotvin bought 5,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $63.14 per share, for a total transaction of $315,700.00. Following the purchase, the executive vice president now directly owns 15,161 shares of the company’s stock, valued at $957,265.54. The disclosure for this purchase can be found here. Insiders sold 9,534 shares of company stock worth $604,560 in the last 90 days. Company insiders own 0.46% of the company’s stock.

CVS Health stock traded down $0.90 during trading hours on Friday, hitting $63.12. 111,709 shares of the stock traded hands, compared to its average volume of 8,132,564. The company has a debt-to-equity ratio of 1.29, a current ratio of 0.99 and a quick ratio of 0.70. The firm’s 50 day moving average price is $64.61 and its 200-day moving average price is $66.29. The stock has a market capitalization of $83.68 billion, a price-to-earnings ratio of 11.60, a P/E/G ratio of 1.41 and a beta of 0.75. CVS Health Corp has a 1 year low of $52.04 and a 1 year high of $77.03.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.28. CVS Health had a return on equity of 15.17% and a net margin of 2.76%. The firm had revenue of $66.76 billion for the quarter, compared to the consensus estimate of $64.11 billion. During the same quarter in the prior year, the business earned $1.62 earnings per share. The company’s revenue was up 8.3% compared to the same quarter last year. Research analysts forecast that CVS Health Corp will post 7.09 earnings per share for the current fiscal year.

Several brokerages recently weighed in on CVS. Oppenheimer restated a “hold” rating on shares of CVS Health in a research note on Wednesday, May 6th. Royal Bank of Canada restated a “buy” rating and set a $77.00 target price on shares of CVS Health in a research note on Wednesday, May 6th. Tigress Financial restated a “buy” rating on shares of CVS Health in a research note on Friday, April 24th. ValuEngine downgraded CVS Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 30th. Finally, Credit Suisse Group upgraded CVS Health from a “neutral” rating to an “outperform” rating and set a $75.00 target price on the stock in a research note on Thursday, May 14th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $80.88.

CVS Health Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Article: Technical Indicators – What is a Golden Cross?

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.